MedTrace Logo

Clinical Trial of Pancreatic Cancer in Stockholm.

NCT02162823 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2023-10-24

No results posted yet for this study

Summary

SPP study includes incidence cases of pancreatic cancer in the Stockholm county region from 2007 to 2014. The purpose of SPP study is to estimate relative risk of pancreatic cancer in relation to snuff dipping, overweight/obesity, individual food items, food groups, dietary pattern and various nutrients; to estimate relative risk of pancreatic cancer in relation to exposure to nitrosamines, either endogenously or exogenously; to estimate relative risk of pancreatic cancer in relation to oral health and H.pylori infection and their interaction with ABO blood type; to estimation relative risk of pancreatic cancer in relation to hepatitis B or hepatitis C infection; to estimate relative risk of pancreatic cancer in relation to some genetic polymorphisms, either functional or being suggested in GWAS study; to estimate mutation profile in pancreatic cancer cases, and its correlation with environmental exposures, and the impacts on survival periods in pancreatic cancer patients.

The MeSH name is Carcinoma, Pancreatic Ductal

Conditions

Interventions

PROCEDURE

Pancreatic Surgery

Surgical removal of the pancreatic tumour (cancer) in the intervention group

Sponsors & Collaborators

  • Karolinska University Hospital

    lead OTHER

Principal Investigators

  • Matthias Löhr, Professor · Karolinska University Hospital

  • Magnus Nilsson, ass prof · Karolinska University Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02162823 on ClinicalTrials.gov